Trial Profile
A Phase II Trial of First-Line Therapy With Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2013
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Jul 2010 Actual end date (December 2009) added as reported by ClinicalTrials.gov.
- 26 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Oct 2007 Status changed from recruiting to in progress.